Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester.
NEJM Evid. 2023 Aug;2(8):EVIDe2300126. doi: 10.1056/EVIDe2300126. Epub 2023 Jul 25.
In this issue of , Maher et al. report the results of a randomized, controlled, 22-day treatment crossover trial comparing the antitussive effect of extended-release nalbuphine, an opioid agonist-antagonist, with placebo in a cohort of patients with definite or probable idiopathic pulmonary fibrosis (IPF). In this small, short-term trial of 38 evaluable patients, the active drug was associated with a 75.1% reduction in daytime objective cough frequency (the primary outcome) compared with a 22.6% reduction in placebo-treated patients, yielding a substantial and statistically significant 52.5 percentage point placebo-adjusted change from baseline.
本期 杂志中，Maher 等人报告了一项为期 22 天的随机、对照、交叉治疗试验的结果，该试验比较了延长释放型纳布啡（一种阿片类激动-拮抗剂）与安慰剂在一组明确或可能特发性肺纤维化（IPF）患者中的镇咳效果。在这项纳入 38 例可评估患者的小型短期试验中，与安慰剂组患者的 22.6%减少相比，活性药物使日间客观咳嗽频率（主要结局）降低了 75.1%，从基线水平调整后的安慰剂效应改变了 52.5 个百分点，具有显著的统计学意义。
